Cancer Vaccines (undisclosed)
Cancer
Pre-clinicalActive
Key Facts
About Takis
Takis is a private, Rome-based biotech firm operating as both a service provider (CRO) and a therapeutic developer. Its core focus is on discovering and developing novel immunotherapies, primarily therapeutic antibodies and DNA/mRNA vaccines for oncology and infectious diseases. The company possesses over a decade of experience in drug discovery, validated preclinical models, and advanced manufacturing capabilities, positioning it as a specialized partner in the European biotech ecosystem. While it advances its own pipeline candidates towards early-phase trials, its service arm generates revenue through collaborations with pharmaceutical and research clients.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |